TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36196060
Drug: Time-to-diuretics administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time-to-diuretics administered between hospital arrival and 8 hours post-hospital arrival
Study: 36196777
Drug: Fenfluramine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine (0.2 mg/kg/day, titrated by effectiveness and tolerability)
Study: 36196899
Drug: Nebulized morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized morphine (nMOR) 10 mg
Study: 36197661
Drug: Apremilast 30
Normalized name: apremilast 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apremilast 30 mg orally twice daily
Study: 36197706
Drug: Bolstered usual
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolstered usual care (literature on antiretroviral therapy adherence promotion and stigma reduction)
Study: 36198179
Drug: IVIG (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG (2.0 g/kg every 4 weeks for 16 weeks)
Study: 36198471
Drug: Machine learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine learning (ML) algorithm for reading WB-MRI scans
Study: 36198471
Drug: ML-assisted reading
Approvals — FDA: no, EMA: no, PMDA: no
Description: ML-assisted reading
Study: 36198471
Drug: Experienced readers
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experienced readers with ML
Study: 36198471
Drug: Experienced readers
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experienced readers without ML
Study: 36198701
Drug: Non-invasive spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-invasive spinal neuromodulation during activity-based neurorehabilitation therapy (ABNT), 2x/week for 8 weeks
Study: 36198701
Drug: Activity-based neurorehabilitation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activity-based neurorehabilitation therapy (ABNT) alone
Study: 36200380
Drug: Frontline treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frontline treatment for Hodgkin lymphoma
Study: 36200417
Drug: Tucidinostat 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tucidinostat 40 mg twice per week (BIW)
Study: 36200668
Drug: Spartalizumab monotherapy
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Spartalizumab monotherapy
Study: 36200701
Drug: Nirmatrelvir/ritonavir treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nirmatrelvir/ritonavir treatment
Study: 36201124
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with glucocorticoids
Study: 36201124
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with rituximab
Study: 36201545
Drug: Fluoroquinolones and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoroquinolones and other antibiotics (post-hoc analysis excluding ophthalmic drops)
Study: 36201545
Drug: Oral Fluoroquinolones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Fluoroquinolones
Study: 36203544
Drug: Abatacept (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abatacept (10 mg/kg, maximum dose 1000 mg) plus standard of care (SOC)
Study: 36203563
Drug: BNT162b2 (0.3ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 (0.3ml intramuscular, homologous)
Study: 36203563
Drug: CoronaVac (0.5ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoronaVac (0.5ml intramuscular, homologous)
Study: 36203563
Drug: CoronaVac (0.5ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoronaVac (0.5ml intradermal)
Study: 36203563
Drug: BNT162b2 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 (2 doses intramuscular, 1 dose intradermal)
Study: 36203760
Drug: Portable sauna
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Portable sauna bath (30-min, 45°C sauna bath, daily for 10 days)
Study: 36203975
Drug: 0.65 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.65 mg/kg r-tPA
Study: 36203975
Drug: 0.90 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.90 mg/kg r-tPA
Study: 36204243
Drug: Venglustat 8
Normalized name: Venglustat
DrugBank: Venglustat (DB14966)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venglustat 8 mg once daily
Study: 36481125
Drug: Venglustat 15
Normalized name: Venglustat
DrugBank: Venglustat (DB14966)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venglustat 15 mg once daily
Study: 36204243
Drug: Venglustat (preferred
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venglustat (preferred dose based on stage 1 safety data)
Study: 36204820
Drug: Ciltacabtagene autoleucel
Normalized name: ciltacabtagene autoleucel
DrugBank: Ciltacabtagene autoleucel (DB16738)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciltacabtagene autoleucel (cilta-cel) at a targeted dose of 0.75 × 10^6 CAR T cells/kg
Study: 36205514
Drug: AVT02 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVT02 administered subcutaneously via autoinjector (AI), 40 mg, for 8 weeks
Study: 36205514
Drug: AVT02 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVT02 administered via prefilled syringe in the extension phase
Study: 36206041
Drug: Pemigatinib, 13.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemigatinib, 13.5 mg orally once daily for 14 consecutive days, followed by 7 days off therapy
Study: 36206189
Drug: FLASH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLASH therapy (8 Gy in a single fraction delivered at ≥40 Gy per second)
Study: 36206189
Drug: FLASH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLASH therapy
Study: 36207609
Drug: Platinum-based chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-based chemotherapy (PtCT) in gBRCA1/2m carriers (N=300)
Study: 36207609
Drug: Non-platinum-based chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-platinum-based chemotherapy (non-PtCT) in gBRCA1/2m carriers (N=300)
Study: 36207609
Drug: Platinum-based chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-based chemotherapy (PtCT) in gBRCA1/2wt patients (N=922)
Study: 36207609
Drug: Non-platinum-based chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-platinum-based chemotherapy (non-PtCT) in gBRCA1/2wt patients (N=922)
Study: 36209118
Drug: Study medication
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study medication (all types)
Study: 36209118
Drug: Treatment guidelines
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment guidelines adherence
Study: 36209441
Drug: FIL200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: FIL200 mg
Study: 36209441
Drug: FIL100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: FIL100 mg
Study: 36210252
Drug: Altruism-tailored educational
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Altruism-tailored educational intervention (spoken and written communication) highlighting altruistic benefits of accepting the seasonal influenza vaccine.
Study: 36210299
Drug: sEphB4-HSA 1000
Normalized name: 125 I HSA
DrugBank: Albumin iodinated I-125 serum (DB09429)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sEphB4-HSA 1000 mg IV administered every 2 weeks, extending to 3 weeks starting from cycle 7
Study: 36211588
Drug: PCSK9 inhibitor
Normalized name: PCSK9 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCSK9 inhibitor (alirocumab)
Study: 36211944
Drug: Ad libitum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad libitum drinking of a cool sport drink (237 mL every 15-20 min)
Study: 36212652
Drug: Aricept and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aricept and Sodium Oligomannate (previous treatments)
Study: 36212980
Drug: Intravesical Ty21a
Normalized name: Typhoid Vaccine Live Ty21a
DrugBank: Typhoid Vaccine Live (DB11050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical Ty21a treatment
Study: 36212980
Drug: Standard BCG
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard BCG treatment
Study: 36213913
Drug: Isha Kriya
Normalized name: CAMPHOR, (-)- 1 g in 100 g TOPICAL PATCH [iShancare Back Pain Patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isha Kriya meditation practice, performed daily for 6 weeks.
Study: 36214278
Drug: Eating disorders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eating disorders (ED) treatment
Study: 36215065
Drug: Less intense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less intense treatment for breast cancer
Study: 36215115
Drug: Color flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Color flow Doppler ultrasound with 1 mL normal saline injection
Study: 36215115
Drug: Color flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Color flow Doppler ultrasound with 1 mL air/saline mixture
Study: 36215232
Drug: Subcutaneous infusion
Normalized name: subcutaneous infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous infusion of 235 ml isotonic saline containing a technetium-99m pertechnetate tracer
Study: 36215912
Drug: High Drug
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Drug Use class
Study: 36269898
Drug: Ciltacabtagene autoleucel
Normalized name: ciltacabtagene autoleucel
DrugBank: Ciltacabtagene autoleucel (DB16738)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciltacabtagene autoleucel (cilta-cel) infusion
Study: 36216013
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of BNT162b2
Study: 36216013
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of BNT162b2
Study: 36216013
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of BNT162b2 (less than 3 months after third dose)
Study: 36216013
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of BNT162b2 (3 months or more after third dose)
Study: 36217101
Drug: HSK3486 (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK3486 (IV bolus dose of 0.4 mg/kg and maintenance infusion of 0.4 mg/kg/h)
Study: 36219274
Drug: Osilodrostat; median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osilodrostat; median average dose was 10.6 mg/day (1.1-47.9)
Study: 36219388
Drug: Long-acting β2-agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting β2-agonists (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combination (FDC)
Study: 36219705
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of sulfadoxine-pyrimethamine
Study: 36219705
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of dihydroartemisinin-piperaquine (DP)
Study: 36219705
Drug: Monthly DP
Normalized name: prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Monthly DP during pregnancy
Study: 36219705
Drug: Monthly DP
Normalized name: prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Monthly DP from 2 to 24 months of age
Study: 36220152
Drug: Once-weekly 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly 300 mg marstacimab
Study: 36220152
Drug: Once-weekly 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly 150 mg marstacimab (after a 300 mg loading dose)
Study: 36220196
Drug: Insulin resistance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin resistance assessed by the insulin sensitivity index (ISI)
Study: 36220315
Drug: Quality of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quality of life and daily physical activity assessment in children and adolescents with IBD
Study: 36220852
Drug: Palbociclib plus
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib plus aromatase inhibitor (AI)
Study: 36221952
Drug: FOLFIRINOX chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRINOX chemotherapy followed by gemcitabine-based chemoradiation
Study: 36223060
Drug: Halobetasol Proprionate
Normalized name: Halobetasol Propionate
DrugBank: Ulobetasol (DB00596)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halobetasol Proprionate 0.01% plus Tazarotene 0.045% (HP/Taz) lotion
Study: 36223228
Drug: ACM-Beta spike
Normalized name: spike lavender oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACM-Beta spike vaccine
Study: 36223228
Drug: ACM-WT spike
Normalized name: spike lavender oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACM-WT spike vaccine
Study: 36223228
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) immunization
Study: 36223228
Drug: Intranasal (IN)
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal (IN) immunization
Study: 36223228
Drug: ACM-polymersome-based Covid-19
Normalized name: covid-19, RNA-based vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACM-polymersome-based Covid-19 vaccine
Study: 36223740
Drug: PARP inhibitor
Normalized name: Poly (ADP-ribose) polymerase (PARP) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: PARP inhibitor olaparib
Study: 36223740
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CD47 antibodies and olaparib
Study: 36223961
Drug: Rituximab (RTX)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab (RTX) - single intravenous infusion of 375 mg/m²
Study: 36223961
Drug: Standardised corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised corticosteroid treatment
Study: 36224176
Drug: Pembrolizumab, trastuzumab,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab, trastuzumab, and doublet chemotherapy
Study: 36226495
Drug: Mivavotinib (TAK-659)
Normalized name: Mivavotinib
DrugBank: Mivavotinib (DB16849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivavotinib (TAK-659) 140 mg QD
Study: 36226495
Drug: Mivavotinib (TAK-659)
Normalized name: Mivavotinib
DrugBank: Mivavotinib (DB16849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivavotinib (TAK-659) 60 mg BID
Study: 36228112
Drug: Topical bexarotene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical bexarotene
Study: 36228644
Drug: Single-dose carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-dose carboplatin (AUC 7) followed by involved-node radiotherapy (30 Gy in 15 fractions for stage IIA and 36 Gy in 18 fractions for stage IIB)
Study: 36228644
Drug: Single-dose carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-dose carboplatin (AUC 7) followed by involved-node radiotherapy
Study: 36228746
Drug: Nivolumab with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab with 70 Gy intensity modulated radiation therapy and weekly cisplatin (arm 1)
Study: 36228746
Drug: Nivolumab with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab with 70 Gy intensity modulated radiation therapy and every 3-week cisplatin (arm 2)
Study: 36228746
Drug: Nivolumab with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab with 70 Gy intensity modulated radiation therapy and cetuximab (arm 3)
Study: 36229024
Drug: Probiotics (Actiregularis,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (Actiregularis, 5×10^6) added to the diet of mothers once daily for 15 days
Study: 36229089
Drug: Sacubitril/Valsartan (Sac/Val)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/Valsartan (Sac/Val) - Low Dose (112 mg)
Study: 36229089
Drug: Sacubitril/Valsartan (Sac/Val)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/Valsartan (Sac/Val) - Moderate Dose (342 mg)
Study: 36229089
Drug: Sacubitril/Valsartan (Sac/Val)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/Valsartan (Sac/Val) - High Dose (379 mg)
Study: 36229089
Drug: Sacubitril/Valsartan (Sac/Val)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/Valsartan (Sac/Val) - All doses
Study: 36229741
Drug: Narrow diameter
Normalized name: narrowleaf marshelder pollen extract
DrugBank: Iva angustifolia pollen (DB10968)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrow diameter implants in T2DM patients
Study: 36229741
Drug: Narrow diameter
Normalized name: narrowleaf marshelder pollen extract
DrugBank: Iva angustifolia pollen (DB10968)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrow diameter implants in normo-glycemic patients
Study: 36229741
Drug: Narrow diameter
Normalized name: narrowleaf marshelder pollen extract
DrugBank: Iva angustifolia pollen (DB10968)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrow diameter implants (general)
Study: 36229853
Drug: DZD2269 (A2aR
Approvals — FDA: no, EMA: no, PMDA: no
Description: DZD2269 (A2aR antagonist)
Study: 36229853
Drug: DZD2269 (A2aR
Approvals — FDA: no, EMA: no, PMDA: no
Description: DZD2269 (A2aR antagonist) in combination with immune checkpoint inhibitors, radiotherapy, or chemotherapy
Study: 36230640
Drug: Intensified NILG-AML
Normalized name: AML-2-23
DrugBank: AML-2-23 (DB17433)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified NILG-AML 01/00 protocol (high dose of ARAC plus idarubicin consolidation)
Study: 36230669
Drug: Oral swab
Normalized name: Moi-Stir, oral swab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral swab assessment before RT
Study: 36233712
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Insomnia (6 weekly sessions)
Study: 36233717
Drug: Invasive endovascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive endovascular treatment
Study: 36237914
Drug: SGLT2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT2 inhibitors (SGLT2-i)
Study: 36237914
Drug: Non-SGLT2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-SGLT2 inhibitors (control group)
Study: 36238465
Drug: Maternal-infant biological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal-infant biological samples (blood, feces, saliva, urine, and breast milk) collected during pregnancy and the first year of life.
Study: 36239199
Drug: Dextromethorphan 15
Normalized name: dextromethorphan 15 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan 15 mg t.i.d.
Study: 36239199
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide inhaler 20 µg 2 puffs t.i.d.
Study: 36239199
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of honey t.i.d.
Study: 36239473
Drug: Pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin (PLD) 30 mg/m2 on day 1 combined with ifosfamide (IFO) 1.8 g/m2 on days 1-5 every 21 days for up to six cycles
Study: 36239788
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and No chemotherapy
Study: 36239858
Drug: Tumor Treating
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor Treating Fields (TTFields) therapy (200 kHz)
Study: 36239955
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both email reminders and personalized telephone outreach
Study: 36240323
Drug: β-hydroxybutyrate (βOHB)
Normalized name: 4-hydroxybutyric acid
DrugBank: gamma-Hydroxybutyric acid (DB01440)
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-hydroxybutyrate (βOHB) infusion
Study: 36240755
Drug: Fourth dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fourth dose of BNT162b2 vaccine
Study: 36240755
Drug: B cell-depleting
Approvals — FDA: no, EMA: no, PMDA: no
Description: B cell-depleting therapies within 12 months before vaccination
Study: 36241982
Drug: 0.5 ml
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml subcutaneous injection of SPIO with 30-s massage
Study: 36241982
Drug: 1.0 ml
Normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 ml intracutaneous injection of SPIO with 2-min massage
Study: 36242742
Drug: Debridement, antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Debridement, antibiotics and implant retention (DAIR) with rifampicin
Study: 36242742
Drug: Debridement, antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Debridement, antibiotics and implant retention (DAIR) without rifampicin
Study: 39031276
Drug: Upadacitinib 15
Normalized name: upadacitinib 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upadacitinib 15 mg (UPA15)
Study: 36401761
Drug: Upadacitinib 30
Normalized name: upadacitinib 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upadacitinib 30 mg (UPA30)
Study: 37982966
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg (ADA)
Study: 36244985
Drug: Neck Disability
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neck Disability Index (NDI-G)
Study: 36245729
Drug: Fecal calprotectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal calprotectin measurement (≥100 μg/g)
Study: 36245729
Drug: Fecal calprotectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal calprotectin measurement (<100 μg/g)
Study: 36246814
Drug: 0.5 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/d ETV (Group A)
Study: 36247059
Drug: Mandibular overdentures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular overdentures assisted by two ultrashort implants with PBM therapy (Dose A: 3.75 J/cm²)
Study: 36247059
Drug: Mandibular overdentures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular overdentures assisted by four ultrashort implants with PBM therapy (Dose A: 3.75 J/cm²)